Clinical Data

positive negative up down good bad mixed
Biotech

Incyte posts phase 3 skin condition wins but details disappoint

With the response rate down on phase 2, the results drew unfavorable comparisons to rival data and triggered a 15% drop in the biotech’s share price.
Nick Paul Taylor Mar 17, 2025 8:12am
An arrow incrementally going up stairs before pointing straight up Blue background

AstraZeneca's $800M rare disease bet hits primary phase 3 goal

Mar 17, 2025 7:25am
whale jumping out of water

Orca prepares to make market plunge after phase 3 win

Mar 17, 2025 7:00am
HIV AIDS PREP

GSK posts data on HIV assets vying for roles in 6-month combo

Mar 12, 2025 11:25am
Kidneys brightly lit

Arrowhead shares ‘select’ data for RNAi asset in kidney trial

Mar 10, 2025 11:55am
obesity overweight weight loss weigh

Novo links CagriSema to 16% weight loss, sending stock down

Mar 10, 2025 9:30am